As previously announced on April 20, 2026, the Company’s Board of Directors authorized a formal review of strategic alternatives to maximize shareholder value. The Company continues to execute on its strategic and operating initiatives during the review process. “As we continue our strategic alternatives review, we expect the compelling fundamentals of the LineaRx business will be central to our evaluation,” said CEO Clay Shorrock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNBX: